Understanding the FDA Approval of Abemaciclib in Early Breast Cancer Treatment

This chapter explores the FDA's approval of abemaciclib as an adjuvant therapy for early-stage hormone receptor-positive HER2-negative breast cancer, highlighting key findings from the Monarchy trial. The host examines patient eligibility, treatment implications, potential side effects, and broader trends in oncology drug approvals.